Related Experiment Video

Updated: Jan 1, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.7K

Circulating Hsp90 Isoform Levels in Overweight and Obese Children and the Relation to Nonalcoholic Fatty Liver

Anca Bălănescu1,2, Iustina Stan1,2, Ioana Codreanu1,2

  • 1Pediatrics Chair, University of Medicine and Pharmacy "Carol Davila", 37 Dionisie Lupu Street, Bucharest, Romania.

Disease Markers
|December 31, 2019
PubMed

Insights

Heat shock protein 90 (Hsp90) beta levels are elevated in obese children, potentially serving as a biomarker for nonalcoholic fatty liver disease (NAFLD). Analyzing Hsp90 isoforms separately offers better diagnostic accuracy for NAFLD in pediatric obesity.

Area of Science:

  • Pediatric Endocrinology
  • Hepatology
  • Biomarker Discovery

Background:

  • Childhood obesity is a growing health concern with associated comorbidities like nonalcoholic fatty liver disease (NAFLD).
  • Heat shock protein 90 (Hsp90) isoforms have been implicated as potential biomarkers for NAFLD in prior proteomic studies.
  • This study investigates Hsp90 alpha (Hsp90α) and Hsp90 beta (Hsp90β) in overweight and obese children.

Purpose of the Study:

  • To analyze circulating levels of Hsp90α and Hsp90β in overweight and obese children.
  • To evaluate Hsp90α and Hsp90β as potential biomarkers for NAFLD in this pediatric population.

Main Methods:

  • Serum samples were collected from 68 overweight/obese children and 10 age/gender-matched controls.
  • Enzyme-linked immunosorbent assay (ELISA) was used to quantify Hsp90α and Hsp90β levels.

Main Results:

  • Serum Hsp90β and total Hsp90 levels were significantly higher in overweight and obese children compared to controls.
  • Hsp90α levels did not differ between obese children and controls.
  • Hsp90 isoforms showed differential expression in NAFLD patients, with higher Hsp90β and lower Hsp90α in those with NAFLD.
  • The Hsp90α to Hsp90β ratio demonstrated superior accuracy for NAFLD diagnosis.

Conclusions:

  • Hsp90 isoforms serve as confirmed biomarkers for NAFLD in overweight and obese children.
  • Separate analysis of Hsp90α and Hsp90β provides greater diagnostic discriminatory power for NAFLD than total Hsp90 measurement in this cohort.
Abstract

More Related Videos

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

7.3K
Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation07:46

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation

Published on: April 3, 2017

25.8K

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
133
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
193
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K